Payers and HTA decision-makers are increasingly demanding evidence that goes beyond what clinical trials capture, including mental health burden, social care resource utilization, and long-term participation outcomes such as employment and income trajectories. Yet, these dimensions are routinely absent from payer-facing narratives, leaving a significant gap in how the true burden of mental health and related conditions is characterized. Part of the reason these dimensions remain absent is that they are rarely captured in secondary real-world data, making linkage across national health and social care records a necessary step.
This webinar explores how linked national data assets, specifically the PHARMO-CBS linkage in the Netherlands, can fill that gap, enabling a more comprehensive and credible assessment of disease burden for HTA submissions. The webinar will also showcase Lumanity’s differentiated data capability through linking PHARMO to CBS data as a credible, payer-relevant approach to burden of illness characterization.
Attendees will gain practical insight into the methods, data, and endpoints that can strengthen value narratives for companies developing assets in mental health, neurodevelopmental, and other complex disease areas.
During this webinar, we will address:
- The methodological gap in HTA submissions: why standard HCRU metrics and secondary real-world data fall short in capturing the full burden of mental health, neurodevelopmental, and other complex disease areas, and what a more complete evidence picture looks like.
- The PHARMO-CBS data asset: an overview of the individual data sources, how they can be linked, and what endpoints and outcomes become measurable through the combined dataset.
- Methods and analytical approach: how the linkage is used in practice, including timelines, data retrieval processes, and the types of analyses that can generate payer-relevant burden of illness estimates.
- Use cases and disease area applications: illustrated through case vignettes spanning conditions such as dementia, ADHD, bipolar disorder, and schizophrenia, demonstrating how the approach translates into actionable evidence for HTA submissions.
Speakers:
- Christoph Abé
Research Manager, PHARMO, part of Lumanity - Brenda Baak
Research Manager, PHARMO, part of Lumanity